Emerging drugs for the treatment of uveitis

被引:10
|
作者
Leung, Theresa G. [1 ]
Thorne, Jennifer E. [2 ,3 ]
机构
[1] Johns Hopkins Univ, Wilmer Eye Inst, Div Ocular Immunol, Sch Med,Dept Ophthalmol, Baltimore, MD 21287 USA
[2] Johns Hopkins Sch Med, Wilmer Eye Inst, Div Ocular Immunol, Baltimore, MD 21287 USA
[3] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA
关键词
biologics; corticosteroids; immunosuppression; ocular inflammation; uveitis; JUVENILE IDIOPATHIC ARTHRITIS; CYSTOID MACULAR EDEMA; LONG-TERM EFFICACY; REFRACTORY UVEITIS; INTERFERON ALPHA-2A; FOLLOW-UP; INTRAVITREAL TRIAMCINOLONE; BEHCETS-DISEASE; CLINICAL-TRIAL; OPEN-LABEL;
D O I
10.1517/14728214.2013.861417
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Uveitis is a potentially visually debilitating disease when untreated or poorly controlled. Chronic intermediate, posterior, or panuveitis often requires systemic immunosuppressive therapy to prevent such visual loss. Areas covered: This review discusses existing treatments for ocular inflammation including corticosteroids, antimetabolites, alkylating agents, T-cell inhibitors, and biologic agents. Potential drugs being studied in clinical trials are introducing new routes for local corticosteroid delivery, and novel immunomodulators are exploring new targets of the inflammatory cascade. Expert opinion: Treatment options for uveitis have expanded from even a decade ago. However, more clinical trials and research are needed to further our understanding of the mechanisms of ocular inflammation and the safety and efficacy of novel therapies.
引用
收藏
页码:513 / 521
页数:9
相关论文
共 50 条
  • [1] Emerging drugs for the treatment of noninfectious uveitis
    Pleyer, Uwe
    Pohlmann, Dominika
    Kardes, Esra
    Poddubnyy, Denis
    Rademacher, Judith
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (03) : 173 - 190
  • [2] Emerging drugs for uveitis
    Larson, Theresa
    Nussenblatt, Robert B.
    Sen, H. Nida
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (02) : 309 - 322
  • [3] TREATMENT OF UVEITIS WITH CYTOSTATIC DRUGS
    DEGN, T
    [J]. ACTA OPHTHALMOLOGICA, 1987, 65 (03): : 371 - 371
  • [4] Biologic Drugs for the Treatment of Noninfectious Uveitis
    Ferreira, Lisia Barros
    Smith, Anthony J.
    Smith, Justine R.
    [J]. ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2021, 10 (01): : 63 - 73
  • [5] Behcet's disease uveitis: is there a need for new emerging drugs?
    Tugal-Tutkun, Ilknur
    Ozdal, Pinar Cakar
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (04) : 531 - 547
  • [6] Birdshot uveitis: current and emerging treatment options
    Menezo, Victor
    Taylor, Simon R. J.
    [J]. CLINICAL OPHTHALMOLOGY, 2014, 8 : 73 - 81
  • [7] Emerging drugs for the treatment of acromegaly
    Campana, Claudia
    Corica, Giuliana
    Nista, Federica
    Cocchiara, Francesco
    Graziani, Giulia
    Khorrami, Keyvan
    Franco, Marta
    Boschetti, Mara
    Ferone, Diego
    Gatto, Federico
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (04) : 409 - 417
  • [8] Emerging drugs for the treatment of sepsis
    Heming, Nicholas
    Lamothe, Laure
    Ambrosi, Xavier
    Annane, Djillali
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (01) : 27 - 37
  • [9] Emerging drugs for the treatment of onychomycosis
    Gupta, Aditya K.
    Stec, Nadia
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (04) : 213 - 220
  • [10] Emerging drugs for the treatment of obesity
    Martinussen, Christoffer
    Bojsen-Moller, Kirstine Nyvold
    Svane, Maria Saur
    Dejgaard, Thomas Fremming
    Madsbad, Sten
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2017, 22 (01) : 87 - 99